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Background: LEF1/TCF transcription factors and their activator β-catenin are effectors of the canonical Wnt
pathway. Although Wnt/β-catenin signaling has been implicated in neurodegenerative and psychiatric disorders, its
possible role in the adult brain remains enigmatic. To address this issue, we sought to identify the genetic program
activated by β-catenin in neurons. We recently showed that β-catenin accumulates specifically in thalamic neurons
where it activates Cacna1g gene expression. In the present study, we combined bioinformatics and experimental
approaches to find new β-catenin targets in the adult thalamus.
Results: We first selected the genes with at least two conserved LEF/TCF motifs within the regulatory elements.
The resulting list of 428 putative LEF1/TCF targets was significantly enriched in known Wnt targets, validating our
approach. Functional annotation of the presumed targets also revealed a group of 41 genes, heretofore not
associated with Wnt pathway activity, that encode proteins involved in neuronal signal transmission. Using custom
polymerase chain reaction arrays, we profiled the expression of these genes in the rat forebrain. We found that nine
of the analyzed genes were highly expressed in the thalamus compared with the cortex and hippocampus.
Removal of nuclear β-catenin from thalamic neurons in vitro by introducing its negative regulator Axin2 reduced
the expression of six of the nine genes. Immunoprecipitation of chromatin from the brain tissues confirmed the
interaction between β-catenin and some of the predicted LEF1/TCF motifs. The results of these experiments
validated four genes as authentic and direct targets of β-catenin: Gabra3 for the receptor of GABA neurotransmitter,
Calb2 for the Ca2+-binding protein calretinin, and the Cacna1g and Kcna6 genes for voltage-gated ion channels.
Two other genes from the latter cluster, Cacna2d2 and Kcnh8, appeared to be regulated by β-catenin, although the
binding of β-catenin to the regulatory sequences of these genes could not be confirmed.
Conclusions: In the thalamus, β-catenin regulates the expression of a novel group of genes that encode proteins
involved in neuronal excitation. This implies that the transcriptional activity of β-catenin is necessary for the proper
excitability of thalamic neurons, may influence activity in the thalamocortical circuit, and may contribute to thalamic
pathologies.
Keywords: β-catenin, Wnt, LEF1/TCF, Transcription regulation, Adult brain, Neurons, Thalamus* Correspondence: mwisniew@iimcb.gov.pl
1International Institute of Molecular and Cell Biology, Laboratory of
Neurodegeneration, ul. Ks, Trojdena 4, 02-109 Warsaw, Poland
Full list of author information is available at the end of the article
© 2012 Wisniewska et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Wisniewska et al. BMC Genomics 2012, 13:635 Page 2 of 17
http://www.biomedcentral.com/1471-2164/13/635Background
β-catenin is an armadillo family protein that serves as
a gene expression regulator in canonical Wnt signal-
ing, in addition to its function in cell adhesion [1,2].
The canonical Wnt pathway involves the inhibition of
GSK3α/β (i.e., a negative regulator of β-catenin), dissoci-
ation of the β-catenin destruction complex that contains
APC and Axin proteins, and subsequent accumulation
of the cytoplasmic pool of β-catenin that can translocate
into the nucleus and activate LEF1/TCF transcription
factors [3,4]. The crucial role of this pathway in cell dif-
ferentiation and proliferation is well established, and
mutations in its components lead to severe malforma-
tions in developing embryos and cancer in adults [5].
The nuclear mediators of canonical Wnt signaling in-
clude the transcription factors LEF1, TCF7 (also known as
TCF1), TCF7L1 (also known as TCF3), and TCF7L2 (also
known as TCF4), which are members of the high mobility
group (HMG) family [6-8]. The HMG DNA binding
domain of LEF1/TCFs recognizes the WWCAAAG con-
sensus sequence. The N-terminus of LEF1/TCF recruits
β-catenin, which does not bind to DNA itself but has a
strong transactivation domain. The remaining regulatory
domains and alternatively spliced C-termini of the pro-
teins vary between these members and provide a molecu-
lar basis for the diversity and context dependence of
LEF1/TCFs function. Lef1/Tcf genes are highly expressed
during mouse embryogenesis, but their transcripts are
virtually undetectable postnatally [9,10], except for intes-
tinal and hair follicle stem cells [11,12]. Surprisingly, high
levels of Lef1 and Tcf7l2 expression have been observed in
the thalamus in the adult brain [13-16].
Growing evidence suggests the involvement of canonical
Wnt signaling in the proper functioning of the adult cen-
tral nervous system [17]. Aberrant regulation of this path-
way has been associated with psychotic and affective
disorders (e.g., major depression, bipolar disorder, and
schizophrenia) [18-24] and neurodegenerative diseases
[25-29]. However, the physiological role of Wnt/β-catenin
in the adult brain is far from understood. The transcrip-
tional activity of β-catenin has been implicated in adult
neurogenesis [30-33] and gliogenesis [34]. These functions
resemble the role of Wnt/β-catenin signaling during neur-
onal development. Nonetheless, nuclear β-catenin has also
been shown to accumulate in mature neurons - in hippo-
campal cells upon NMDA (N-Methyl-D-aspartate) recep-
tor activation [35-37] and constitutively in thalamic cells
[38]. The identification of β-catenin target genes in neu-
rons may provide insights into its role in these cells and
the adult brain.
Most of the approximately 100 known β-catenin tar-
gets are involved in development and cancer. In differen-
tiated neurons, only a few genes have been shown to be
activated by β-catenin; several are already known Wnttarget genes that are not neuron-specific [35-37]. As we
recently demonstrated, a new target, Cacna1G, encodes
voltage-gated Ca2+ channels [16]. In this work, we iden-
tified in silico and experimentally validated a novel
group of β-catenin-LEF1/TCF targets in thalamic neu-
rons, consisting of genes that encode proteins that are
important for neuronal function, including voltage- and
ligand-gated ion channels and the Ca2+-binding protein
calretinin. This indicates a role for β-catenin and LEF1/
TCF transcription factors in the maintenance of neu-
ronal excitability.
Results
Putative LEF1/TCF target genes identified in silico
are enriched in known Wnt targets
To find putative β-catenin target genes, we screened for
LEF1/TCF family motifs in rat and human conserved
regions within 10 kb upstream and downstream of tran-
scription start sites (TSSs). We relied on the fact that
enhancers are enriched in proximity to TSSs [39], and
the clustering of TCF7L2-bound regions occurs within
10 kb of TSSs in colorectal cancer [40]. Using estab-
lished bioinformatics tools with their default parameters,
we identified 2,871 genes with at least one rat-to-human
conserved LEF1/TCF motif and 851 genes that contain
at least two LEF1/TCF motifs in the same conserved
noncoding sequences (CNSs). These two lists were com-
pared with experimentally established Wnt target genes
cataloged at http://www.stanford.edu/group/nusselab/
cgi-bin/wnt/target_genes (accessed January 11, 2012;
Figure 1). The degree of overlap between our lists and
the list on the Wnt homepage shows that the Wnt tar-
gets are highly overrepresented among the genes that
contain the predicted conserved LEF1/TCF binding site.
This positively validated our bioinformatics approach to
identifying LEF1/TCF targets. For further analysis, we
selected only the genes with at least two LEF1/TCF motifs
in one regulatory element, expecting fewer false-positive
hits in this group. This presumption was based on the ob-
servation that more than 30% of the genes that contain
pairs of TCF7L2 motifs in the same CNS display Wnt
target-like patterns during mouse development [41]. We
excluded genes with a “NULL” or “PREDICTED” descrip-
tion in the Ensembl database, creating a final list of
428 rat genes (Additional file 1), which we considered
putative LEF1/TCF targets.
Putative LEF1/TCF targets are enriched in neuron-specific
genes (GO analysis)
We performed a gene ontology (GO) analysis of the
428 putative targets using DAVID Functional Annota-
tion tools (http://david.abcc.ncifcrf.gov; accessed January
11, 2012) to identify functionally related groups of genes.



























Figure 1 Bioinformatics identification of putative LEF1/TCF
target genes. The diagram presents the successive steps to select
putative LEF1/TCF targets, beginning from the group of human-rat
orthologs in the Ensembl database. Groups of genes are in
rectangles, and computational procedures are in diamonds. In the
blue frame, the crossing of our in silico-selected genes with known
Wnt/β-catenin targets is shown. The p values (Fisher’s Exact test)
confirmed the enrichment of genes with at least one and at least
two LEF1/TCF binding sites (predicted with Matinspector using
Genomatix family V$LEFF) with the known targets.
Table 1 Overrepresented GO terms in the predicted LEF1/
TCF target genes
GO term Number of genes p value
Three top terms
Neuron differentiation 67 1.9E-27
Pattern specification 45 3.4E-21
Sequence-specific DNA binding 60 4.7E-21
Selection of other expected terms
Regulation of cell development 35 1.7E-14
Cell migration 33 8.0E-12
Cell proliferation 26 1.75E-7
Cell adhesion 35 1.4E-6
Regulation of cell death 43 9.6E-6
Wnt receptor signaling pathway 11 2.0E-4
Selection of novel terms related to neuronal function
Synapse 32 3.6E-8
Gated-channel activity 20 2.8E-4
The p values are based on DAVID Bioinformatics Resources (see Materials and
Methods).
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tion (Table 1). Other predictable categories of molecular
function and biological processes were overrepresented:
specific DNA binding (transcription factors), Wnt sig-
naling, and cell migration, adhesion, and death. Unex-
pectedly, we found statistically significant enrichment in
genes implicated in neuronal function, including genes
for synaptic proteins and voltage-gated cation channels
(VGCCs). Based on this analysis, we hypothesized that
β-catenin-LEF1/TCF can regulate specific neuronal gen-
etic programs. We collected the genes that were anno-
tated with “synapse” and “gated-channel activity” terms
and included a few other genes that failed to be anno-
tated with the above GO terms, although they obviously
belong to these categories (e.g., the γ-aminobutyric acid
[GABA] receptor-associated protein gene Gabarap).
Several genes were also excluded because they were not
brain-specific (e.g., Chrnd, which encodes a neuromus-
cular cholinergic receptor). The final collection con-
tained 41 putative neuronal LEF1/TCF targets grouped
into five categories: nine VGCCs, 11 neurotransmitterreceptors, eight proteins involved in synaptic vesicle
organization, 10 synaptic structural proteins, and three
other proteins implicated in synaptic transmission
(Table 2). All of these gene targets were chosen for ex-
perimental validation.
VGCC genes with conserved LEF1/TCF motifs compared
with all other VGCC genes display preferential expression
in the thalamus (RT-qPCR arrays)
To initially validate our bioinformatics predictions, we
concentrated on the VGCC group. The relative mRNA
levels of the ensemble of VGCC genes were measured in
three different parts of the forebrain: thalamus, cortex,
and hippocampus. We expected that the VGCC genes
that are postulated LEF1/TCF targets would be preferen-
tially expressed in the thalamus because nuclear β-
catenin and LEF1 and TCF7L2 transcription factors are
present in thalamic neurons but not cortical or hippo-
campal neurons [13-16]. The comparative expression
analysis was performed using custom-designed quantita-
tive real-time polymerase chain reaction (RT-qPCR)
arrays with six independent preparations from each
brain region. The arrays contained all VGCC genes that
have CNSs (Table 3), excluding a few genes that are
known to be expressed only in non-neuronal tissues.
The expression of 53 of the 55 VGCC genes was
detected in the forebrain; no signal was obtained for
Kcnip1 and Kcnj1. Four of nine putative LEF1/TCF tar-
get VGCC genes were expressed at least two-fold higher
in the thalamus than in the cortex and hippocampus,
and none were expressed at a lower level. In the
remaining group of 44 genes, four were expressed at a
Table 2 Putative LEF1/TCF target genes that encode proteins with specific neuronal functions
No. Gene symbol (RGD) Protein name; description
Voltage-gated cation channels
1 Cacna1g Ca2+ channel, voltage-gated, α1G subunit
2 Cacna2d1 Ca2+ channel, voltage-gated, α2/δ1 subunit
3 Cacna2d2 Ca2+ channel, voltage-gated, α2/δ2 subunit
4 Kcna1 K+ voltage-gated, shaker-related subfamily member 1
5 Kcna6 K+ voltage-gated, shaker-related subfamily member 6
6 Kcnh4 K+ voltage-gated, subfamily H member 4
7 Kcnh8 K+ voltage-gated, subfamily H member 8
8 Kcnj3 K+ inwardly rectifying channel, subfamily J member 3
9 Scn8a Na+ voltage-gated, type VIII, alpha subunit
Neurotransmitter receptors
10 Cnr1 Cannabinoid CB1 receptor; metabotropic
11 Drd3 Dopamine D3 receptor; metabotropic
12 Gabra3 GABAAα3 receptor; ionotropic (Cl
-)
13 Gabrg2 GABAAγ2 receptor; ionotropic (Cl
-)
14 Glra1 Glycine α1 receptor; ionotropic
15 Gria3 Glutamate AMPA 3 receptor; ionotropic
16 Grid2 Glutamate δ2 receptor; ionotropic
17 Grik3 Glutamate kainate 3 receptor; ionotropic
18 Htr1b 5-hydroxytryptamine (serotonin) 1B receptor; metabotropic
19 Htr3a Serotonin 3A receptor; ionotropic
20 Htr3b Serotonin 3B receptor; ionotropic
Synaptic vesicle proteins
21 Syt1 Synaptotagmin I; membrane protein, Ca2+ sensor involved in vesicle trafficking and neurotransmitter release
22 Syt4 Synaptotagmin IV; membrane protein, vesicle trafficking and neurotransmitter release
23 Syt5 Synaptotagmin V; membrane protein, Ca2+ sensor involved in vesicle trafficking and neurotransmitter release
24 Syt6 Synaptotagmin VI; membrane protein, Ca2+ sensor involved in vesicle trafficking and neurotransmitter release
25 Syt7 Synaptotagmin VII; membrane protein, Ca2+ sensor involved in vesicle trafficking and neurotransmitter release
26 Syp Synaptophysin; synaptic vesicle organization
27 Vamp2 Vesicle-associated membrane protein 2; vesicle transport and membrane fusion during exocytosis
28 Vamp3 Vesicle-associated membrane protein 3; vesicle transport and membrane fusion during exocytosis
Structural synaptic proteins
29 Cdh2 Cadherin 2 (alias N-cadherin); hemophilic cell adhesion molecule in excitatory synapses
30 Cnksr2 Connector enhancer of kinase suppressor of Ras 2; scaffold protein, complex assembly of synaptic proteins
31 Dfnb31 Deafness autosomal recessive 31; PDZ scaffold protein, facilitates synaptic transmission
32 Gabarap GABAA receptor-associated protein; involved in clustering of neurotransmitter receptors
33 Lin7a Homolog a of C. elegans lin-7; PDZ scaffold protein, localizes vesicles and receptors to the plasma membrane
34 Map1b Microtubule-associated protein; involved in synaptic plasticity
35 Mpdz Multiple PDZ domain protein; PDZ scaffold protein, component of NMDA receptor signaling complex
36 Nlgn1 Neuroligin 1; synaptic cell adhesion molecule, maintains synaptic junctions by binding β-neurexins
37 Nlgn2 Neuroligin 2; synaptic cell-adhesion molecule, maintains synaptic junctions by binding β-neurexins
38 Nrxn3 Neurexins 3; synaptic cell-adhesion molecule; maintains synaptic junctions by binding neuroligins
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Table 2 Putative LEF1/TCF target genes that encode proteins with specific neuronal functions (Continued)
Other proteins involved in modulation of signal transmission
39 Gjd2 Gap junction protein delta; member of the connexin family, in gap-junction channels of electrical synapses
40 App Amyloid β (A4) precursor protein; cell surface receptor involved in synaptic plasticity
41 Calb2 Calbindin 2 (alias calretinin); Ca2+-binding protein, modulates neuronal excitability
The gene symbols are based on the Rat Genome Database (RGD).
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lower level (Figure 2A). Fisher’s Exact test, yielding a p
value of 0.021, confirmed a correlation between thalamic
expression and being a putative LEF1/TCF target. This
validated the approach to identifying new LEF1/TCF tar-
gets based on combined in silico binding site prediction
and high expression in the thalamus (i.e., the region with
high levels of nuclear β-catenin and LEF1/TCF factors in
neurons).
More than 20% of neuron-specific genes with conserved
LEF1/TCF motifs are highly expressed in the thalamus
(RT-qPCR arrays)
We next expanded the analysis and profiled the expres-
sion of all 41 genes listed as putative neuronal targets of
LEF1/TCF (Table 2) in the cortex, hippocampus, and
thalamus. Another set of custom-designed RT-qPCR
arrays and the previous six independent preparations
from each brain region were used. Our aim was to
determine which of the predicted targets are highly
expressed in the thalamus, suggesting their actual regu-
lation by β-catenin-LEF1/TCF.
The expression of 40 of the 41 genes was detected in
the forebrain; no signal was obtained for Htr3b. In the
thalamus, nine genes (22.5%) were expressed at least
two-fold higher than in the cortex and hippocampus
(Figure 2B), and the differences were statistically signifi-
cant (Figure 3). In the cortex vs. the other two regions,
two genes (5%) were expressed at a higher level, and no
single gene was highly expressed in the hippocampus
(Figure 2C).
The following genes had higher expression levels in
the thalamus: four VGCC genes (Cacna1g, Cacna2d2,
Kcna6, and Kcnh8, which were also observed in the pre-
vious experiment), four genes that represent neurotrans-
mitter receptors (Drd3, Gabra3, Glra1, and Grid2), and
the Calb2 gene that encodes the Ca2+ buffer calretinin
(Figure 3). The genes from two other categories (i.e., the
genes that encode synaptic vesicle proteins and struc-
tural synaptic proteins; Table 2) did not show specific
thalamic expression.
β-catenin is associated with chromatin at the Cacna1g,
Kcna6, Gabra3, Grid2, and Calb2 loci in the thalamus
Gene profiling in the rat brain allowed us to observe a
positive association between the relative expression ofthe neuronal genes with at least two conserved LEF1/
TCF motifs and the presence of β-catenin and LEF1/
TCF factors in the brain. To determine whether the
β-catenin-LEF1/TCF complex might directly regulate
Cacna1g, Cacna2d2, Kcna6, Kcnh8, Drd3, Gabra3,
Glra1, Grid2, and Calb2, we analyzed the in vivo binding
of β-catenin to LEF1/TCF motifs within the CNSs using
a chromatin immunoprecipitation (ChIP) assay with
designed primers (Figure 4 and Table 4). We also exam-
ined the chromatin conformational state of the frag-
ments that contained conserved LEF1/TCF motifs by
precipitating them with an antibody specific for acetyl-
histone H3 (H3Ac; a hallmark of open chromatin [42,43]).
In each ChIP assay, we compared four independent
samples of chromatin isolated from the cortex, hippo-
campus, and thalamus.
We first assessed the acetylation status of histone H3
at the Gapdh promoter and Gapdh exon, an open and
close chromatin region, respectively. We found high
levels of H3Ac in the promoter while much lower levels
in the first exon. This showed that our ChIP assays to
monitor H3Ac was specific (Figure 5A). We then ana-
lyzed the chromatin conformation of our genes of inter-
est in fragments with conserved LEF1/TCF motifs. The
chromatin fragments that were in close proximity to
TSSs, Cacna1g-3 and Kcnh8-1, appeared to be in an
open state. The same was observed for some fragments
located distally from the TSSs (e.g., Grid2-1, -2, and −3),
whereas other fragments precipitated with low efficiency
(< 1%; e.g., Drd-1 and −2), indicating the closed con-
formation of chromatin (Figure 5A). In most cases,
no differences were found between the analyzed brain
structures. However, some fragments (e.g., Gabra3-1,
Cacna2d2-1, Cacna2d2-2, Cacna2d2-3, and Calb2-3)
precipitated significantly more efficiently from the thal-
amic samples than from the cortex and hippocampus.
We then performed a ChIP assay with an anti-β-catenin
antibody. To determine the background, normal immuno-
globulin G (IgG) was used, which precipitated < 0.02% of
the input. The signals for all of the examined fragments
were at background levels in the case of the cortex and
hippocampus (Figure 5B). However, when the thalamic
samples were used, fragments of Gabra3, Grid2, Cacna1g,
Kcna6, and Calb2 precipitated with anti-β-catenin at
levels of 0.04-0.1% (Figure 5B), indicating the binding of
β-catenin to these fragments. Moreover, for all of these
Table 3 List of genes that encode voltage-gated cation channels included in the custom “VGCC” arrays
No. Gene symbol (RGD) Channel type Subunit type Ensembl gene ID
1 Cacna1g Ca2+ α1, pore ENSRNOG00000002981
2 Cacna1h Ca2+ α1, pore ENSRNOG00000033893
3 Cacna1i Ca2+ α1, pore ENSRNOG00000029914
4 Cacnb1 Ca2+ β, auxiliary ENSRNOG00000004518
5 Cacnb2 Ca2+ β, auxiliary ENSRNOG00000018378
6 Cacnb3 Ca2+ β, auxiliary ENSRNOG00000012489
7 Cacna2d1 Ca2+ α2δ, auxiliary ENSRNOG00000033531
8 Cacna2d2 Ca2+ α2δ, auxiliary ENSRNOG00000015835
9 Cacna2d3 Ca2+ α2δ, auxiliary ENSRNOG00000031287
10 Kcna1 K+ α, pore ENSRNOG00000019750
11 Kcna3 K+ α, pore ENSRNOG00000018116
12 Kcna4 K+ α, pore ENSRNOG00000004918
13 Kcna6 K+ α, pore ENSRNOG00000019753
14 Kcnb1 K+ α, pore ENSRNOG00000008204
15 Kcnb2 K+ α, pore ENSRNOG00000028991
16 Kcnc1 K+ α, pore ENSRNOG00000011380
17 Kcnc2 K+ α, pore ENSRNOG00000004077
18 Kcnc3 K+ α, pore ENSRNOG00000019959
19 Kcnd2 K+ α, pore ENSRNOG00000029610
20 Kcnd3 K+ α, pore ENSRNOG00000014686
21 Kcng3 K+ α, pore ENSRNOG00000004535
22 Kcng4 K+ α, pore ENSRNOG00000015746
23 Kcnh2 K+ α, pore ENSRNOG00000009872
24 Kcnh3 K+ α, pore ENSRNOG00000032075
25 Kcnh4 K+ α, pore ENSRNOG00000018790
26 Kcnh5 K+ α, pore ENSRNOG00000009542
27 Kcnh6 K+ α, pore ENSRNOG00000008078
28 Kcnh7 K+ α, pore ENSRNOG00000007528
29 Kcnh8 K+ α, pore ENSRNOG00000012711
30 Kcnq2 K+ α, pore ENSRNOG00000011624
31 Kcnq3 K+ α, pore ENSRNOG00000005206
32 Kcnq5 K+ α, pore ENSRNOG00000013781
33 Kcns1 K+ α, pore ENSRNOG00000013681
34 Kcns2 K+ α, pore ENSRNOG00000011369
35 Kcns3 K+ α, pore ENSRNOG00000004899
36 Kcnv1 K+ α, pore ENSRNOG00000004117
37 Kcnab2 K+ β, auxiliary ENSRNOG00000011550
38 Kcnab3 K+ β, auxiliary ENSRNOG00000008480
39 Kcnip1 K+ β, auxiliary ENSRNOG00000005365
40 Kcnip2 K+ β, auxiliary ENSRNOG00000018018
41 Kcnip3 K+ β, auxiliary ENSRNOG00000014152
42 Kcnj1 K+, inwardly-rectifying (IR) pore, ENSRNOG00000008779
43 Kcnj2 K+, IR pore, ENSRNOG00000004720
44 Kcnj3 K+, IR pore ENSRNOG00000005369
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Table 3 List of genes that encode voltage-gated cation channels included in the custom “VGCC” arrays (Continued)
45 Kcnj5 K+, IR pore ENSRNOG00000033796
46 Kcnj9 K+, IR pore ENSRNOG00000007645
47 Kcnj10 K+, IR pore ENSRNOG00000007705
48 Kcnj11 K+, IR pore ENSRNOG00000021128
49 Kcnj12 K+, IR pore ENSRNOG00000002303
50 Scn1a Na+ α, pore ENSRNOG00000005989
51 Scn8a Na+ α, pore ENSRNOG00000005309
52 Scn1b Na+ α, pore ENSRNOG00000021102
53 Scn2b Na+ α, pore ENSRNOG00000016221
54 Scnb3 Na+ α, pore ENSRNOG00000006937
55 Scnb4 Na+ α, pore ENSRNOG00000026679
The genes that are putative LEF/TCF targets are in bold.
Wisniewska et al. BMC Genomics 2012, 13:635 Page 7 of 17
http://www.biomedcentral.com/1471-2164/13/635fragments, the differences in chromatin precipitation
levels between the thalamic samples and other samples
were statistically significant. This indicates that the afore-
mentioned genes can be directly regulated by β-catenin
and LEF1/TCF factors. Interestingly, no correlation was
observed between the β-catenin-chromatin interaction
(Figure 5B) and acetylation status of histone H3 in the
chromatin fragments (Figure 5A).
Attenuation of β-catenin signaling leads to decreases in
Cacna1g, Cacna2d2, Kcna6, Kcnh8, Gabra3, and Calb2
expression in cultured thalamic neurons
Finally, we examined the effect of nuclear β-catenin re-
moval in primary thalamic cultures on the expression of
the nine genes identified by gene profiling. The cultures
contained both neurons and glia (approximately 1:1),
which is vital for the survival of thalamic neurons [38].
Thalamic neurons cultured in vitro maintain the nu-
clear localization of β-catenin [38]. To decrease its level,
the cultures were treated with an adenovirus that carried
Axin2, the product of which is a component of the β-
catenin destruction complex and as such should reduce
its cytoplasmic and nuclear pool. The control cultures
were transduced with Gfp-expressing adenovirus. The
percentage of β-catenin-positive neurons decreased from
~40% to 10% in cultures with ectopic Axin2 expression
(Figure 6A). No nuclear β-catenin was detected in glia.
Afterward, the expression levels of the nine genes and
control genes, Map2, Cacna1h, and Lef1, were measured
by RT-qPCR. Similar expression levels of the neuronal
marker Map2 in Gfp- and Axin2- expressing cultures
verified the equal survival and condition of neurons
(Figure 6B). The level of Lef1, serving as a positive con-
trol as a classical target of β-catenin, decreased by ~20%,
confirming the impairment of β-catenin-dependent tran-
scription in the treated cultures. The expression level of
Cacna1h, a paralog of Cacna1g that lacks conserved
LEF1/TCF motifs, was not modified. Of the nineexamined genes, we observed a statistically significant
decrease in the expression of six genes, Cacna1g, Cac-
na2d2, Kcna6, Kcnh8, Gabra3, and Calb2, suggesting
that these genes are authentic targets of β-catenin. The
level of Glra1 expression increased, and Grid2 expres-
sion did not change. Drd3 transcription was not
detected (Figure 6B).
The actual decreases of the expression levels in given
neurons were supposedly several times larger, consider-
ing that the changes in the level of nuclear β-catenin oc-
curred in ~30% of the cultured neurons. This percentage
was estimated based on the following observations: (i)
40% of the neurons were β-catenin-positive in the con-
trol, and (ii) 12% of the neurons still maintained the nu-
clear localization of β-catenin after Axin2 adenovirus
treatment (Figure 6A). The most pronounced effects
were observed for Cacna1g, Kcna6, and Calb2; together
with the ChIP results (Figure 5B), this indicates the high
importance of β-catenin in the regulation of the expres-
sion of these genes in thalamic neurons. The ChIP and
expression results were also consistent for Gabra3 and
corroborated the regulation of this gene by β-catenin.
Discussion
The present study identified five new β-catenin target
genes in thalamic neurons, in addition to previously
described Cacna1g [16]. Three of them, Kcna6, Calb2,
and Gabra3, were validated by ChIP in vivo and a loss-
of-function experiment in cultured neurons, confirming
that they might be directly regulated by β-catenin. Two
other genes, Cacna2d2 and Kcnh8, also displayed β-
catenin-dependence in the latter experiment, although
the binding of β-catenin to their regulatory elements
was not found. Based on these data, we propose that β-
catenin is a regulator of the electrophysiological proper-
ties of thalamic neurons in the adult brain.
Numerous genes that we selected in silico as potentially
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Figure 2 Gene profiling in the forebrain. Scatterplots show mean gene expression fold changes between the thalamus, hippocampus, and
cortex by RT-qPCR. p values (Student’s t-test) revealed statistical significance for all fold changes > 2 and < 0.5. A logarithmic scale is used. Red
frames surround the plot areas of at least two-fold higher expression in a given brain region compared with the other two regions, gray frames -
of at least two-fold lower. (A) Expression of VGCC genes in the thalamus vs. cortex (x-axis) and hippocampus (y-axis). (Left plot) VGCC genes
defined as putative LEF1/TCF targets. (Right plot) Remainder of the VGCC genes. The proportions of highly expressed genes in the group of
putative LEF1/TCF targets (left plot) and in the non-target group (right plot) were compared using Fisher’s Exact test, indicating a nonrandom
association (p = 0.021). (B) Expression of all putative neuronal LEF1/TCF targets in the thalamus vs. cortex (x-axis) and hippocampus (y-axis).
Notice that many genes are highly expressed in the thalamus. (C) Expression of all putative neuronal LEF1/TCF targets. (Left plot) Cortex vs.
thalamus (x-axis) and hippocampus (y-axis). (Right plot) Hippocampus vs. thalamus (x-axis) and cortex (y-axis). Notice that this group of genes is
not preferentially expressed in the cortex or hippocampus. n = 6 independent biological samples.
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http://www.biomedcentral.com/1471-2164/13/635categories: transcription regulation, cell proliferation,
morphogenesis, motility, adhesion, differentiation, and
programmed cell death. Similar clusters were observed
by others in the genes bound by TCF7L2 in a human
colorectal cancer cell line [40]. These results support the
well-established role of Wnt/β-catenin in development.
Interestingly, the genes involved in neuronal differenti-
ation exhibited the highest enrichment scores in our list.
This was consistent with a study that identified β-catenin-LEF1/TCF targets based on a ChIP assay in NIH3T3 cells.
Thirty percent of the target genes were implicated in devel-
opmental processes, and more than half of the targets from
this group were involved in neuronal development [44].
Indeed, Wnt signaling has been particularly implicated in
central nervous system development, from early brain pat-
terning to embryonic and adult neurogenesis [30-33,45-50].
Although our in silico analysis corroborated the involve-
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Figure 3 Expression analysis of putative LEF1/TCF targets in the forebrain. Volcano plots arrange genes along the dimensions of (x) mean
expression fold difference between two brain structures and (y) p value (Student’s t-test). A logarithmic scale is used. Red frames surround the
plot area, in which the expression in the thalamus is at least two-fold higher than in the other structures, and the difference is statistically
significant (p < 0.05). The genes inside the frames are considered likely LEF1/TCF targets in the thalamus. On every plot, the genes that met the
criterion of a statistically significant two-fold expression difference between the two structures are labeled. Those that are higher in the thalamus
vs. cortex and hippocampus are in green. n = 6 independent biological samples.
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http://www.biomedcentral.com/1471-2164/13/635groups of genes, it also identified a group that has not
been previously proposed to be a β-catenin-LEF1/TCF tar-
get. These were the genes of proteins involved in signal
transmission in neurons, including voltage-gated ion
channels, neurotransmitter receptors, synaptic vesicle pro-
teins, and synaptic structural proteins. Moreover, we pro-
vided experimental evidence of the authentic regulation of
some of these genes by β-catenin. The above gene clusters
have not yet been identified, probably because the screen-
ings for β-catenin target genes were performed on estab-
lished cell lines or cancer cells [40,44,51-54]. Additionally,
studies of hippocampal neurons, in which β-catenin
nuclear translocation was observed after NMDA stimula-
tion, did not attempt to identify specific neuronal targets
[35-37].
While examining the β-catenin-chromatin association
and acetylation of histone H3, we did not observe any
relationship between these two phenomena in the ana-
lyzed regions with the LEF1/TCF motif. This suggests
that the interaction between the β-catenin-LEF1/TCF
complex and DNA might not require the open conform-
ation of chromatin. These results may also suggest that
the β-catenin complex does not always increase histone
acetylation, although it potentially has such an ability
[55,56]. This is consistent with a recent study performed
on embryonic stem cells, in which knockdown of Tcf7
and Tcf7l2 did not affect the active chromatin conform-
ation of their targets [57]. We also noticed an interesting
pattern of LEF1/TCF motif occurrence in the examined
genes. The motifs were usually clustered downstream of
the first exon and not in the promoter regions. This sug-
gests that the transcription of these genes may be regu-
lated by LEF1/TCF factors by gene looping, which hasbeen demonstrated for the COX2 and MMP13 genes,
in which LEF1/TCF binding sites were located in the 30
untranslated region [58].
The neuronal genes with conserved LEF1/TCF motifs
that were highly expressed in the thalamus, the regulation
of which by β-catenin was confirmed experimentally, en-
code proteins involved in neuronal excitability. Cav3.1
(encoded by Cacna1g), Cavα2δ2 (Cacna2d2), Kv1.6
(Kcna6), Kv12.1/ELK1 (Kcnh8), and GABAA receptor 3
(Gabra3) are all voltage- or ligand-gated ion channels
[59-61]. As such, they underlie the cell membrane con-
ductance of Ca2+, K+, and Cl- (in the case of the GABA
receptor) ions and directly propagate, inhibit or modify
electric signals [62-64]. Calretinin, in turn, is an intracel-
lular Ca2+-binding protein [65,66] with diverse functions,
including the modulation of intrinsic neuronal excitability
[67]. We propose that β-catenin contributes to the proper
excitability of thalamic neurons by regulating the expres-
sion of the above genes. However, more research is
required to determine the real impact of β-catenin and
LEF1/TCF factors on the expression of the identified
genes and electrophysiology of the thalamus.
The other classes of putative neuronal targets of LEF1/
TCF (i.e., the genes that encode structural synaptic pro-
teins, mainly with the PDZ domain, and synaptic vesicle
proteins) did not show high expression in the thalamus.
However, they still might be regulated by β-catenin and
LEF1/TCF factors in some subtypes of neurons or under
specific physiological conditions because the regulation of
gene expression by β-catenin is very much context-
dependent [8,44,68,69]. Particularly interesting would be
the exploration of this possibility in future research be-
cause a membranous fraction of β-catenin interacts with
4321
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Figure 4 Positions of LEF1/TCF motifs in the conserved noncoding sequences in the genomic flanks of the transcription start sites of
genes selected for experimental validation. The schemes represent Drd3, Gabra3, Glra1, Grid2, Cacna1g, Cacna2d2, Kcna6, Kcnh8, and Calb2
genes. The plots are on the gene strand, nucleotide positions are given relative to the transcription start site (TSS) of each gene, as defined in the
Ensemble version used. For Gabra3, an alternative TSS prediction, marked with the asterix, based on the NCBI Reference Sequence NM_017069.3,
is also shown. CNSs are represented as green rectangles. Positions of LEF1/TCF motifs (analyzed only in the CNSs) are marked as red bars, above
or below the axis depending on the strand. Exons within the analyzed flanks (for majority of the genes – only the first exons) are shown as black
rectangles on the axis. Amplicons used in the ChiP assay are shown as numbered thick black lines.
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http://www.biomedcentral.com/1471-2164/13/635PDZ proteins in synapses and is implicated in synaptic
vesicle localization [70-73]. The role of nuclear β-catenin
in the regulation of PDZ and synaptic vesicle protein ex-
pression might complement the function of membranous
β-catenin in neurons.
We do not yet know whether variations in the nuclear
level of β-catenin affect the expression of genes that encode
VGCCs and neurotransmitter receptors and shape neur-
onal excitability in vivo. If so, then we could speculate that
the inappropriate activity of β-catenin might affect proper
signal transmission in thalamocortical circuits. Thalamocor-
tical desynchronization underlies absence epilepsy [74], and
many anticonvulsant drugs target voltage-gated channels
(e.g., T-type Ca2+ channels [63]). Specifically, the T-typevoltage-gated channel Cav3.1 has been proposed to be
implicated in absence seizures [75,76], in addition to the
Cavα2δ2 regulatory subunit of voltage-gated channels [77]
and GABAA receptor 3 [78]. Schizophrenia has also been
associated with thalamic dysfunction [79-84]. Moreover,
some variants of Tcf7l2 have been recently shown to be a
risk factor in schizophrenia [23,85], and a group of synaptic
genes involved in excitability has been found to be asso-
ciated with the risk of schizophrenia [86]. Interestingly,
Gabra3-deficient mice display impairments in sensorimotor
gating, which is a feature of this disorder [87]. These results
suggest a possible role for β-catenin-dependent gene ex-
pression in thalamic pathologies, but further in vivo studies
are required to elucidate this issue.
Table 4 List of primers used in chromatin immunoprecipitation assay
PCR amplicon Forward primer Reverse primer
Cacna1g - 1 TCAACCTTGCCAGCAAGTCAAAGC ACAGGCAAGAGGGCTACATGAACT
Cacna1g - 2 AAAGATGTCAGAGGCCGGTTGG TCCAGACCGAACCCACTTTCCTAT
Cacna1g - 3 AAGCGAAGAAGCCGGAACAAAGTG GCTCTAGAGAGCTTGCTGAGTCCC
Cacna1g - 4 GTGCGAAAGTGCGTGGTAAACTGT AGGCTCCGTGAGTTTGCTGTGAAT
Cacna2d2 - 1 ACCATGCCTTAGCCATATGCCAGT TCTCCTCAAAGCCGAGGACAGAAA
Cacna2d2 - 2 GGGTTAGTGGGTTGTGGTATTGTC TTCGAGGAGCTGGGAAGCTAAGAA
Cacna2d2 - 3 TATCTCTGCAGCCAGAATGTGCTC AGGCTTTGTTTCTCACTGCCAACG
Kcna6 - 1 AAGGTAACTCGGTGGTTCCCACTT AATGGCAATGTTATGGGAGGGAGG
Kcna6 - 2 TGTCACCCTCATCACTATCCCTGT AGCTGGGATATGTAGTCTGTTCCC
Kcnh8 - 1 TTACCTGCAGTGACCTGTCTCCT AAACGCGAGTCAGAGCAACTCC
Kcnh8 - 2 CTAAATGTATTCACTGTTCAAAGC GTCAGCAAATTCTAAGCATCA
Drd3 - 1 GGCAATTAAACTGAGGATGGTGAG TCCCTCTGAGGCTCTATCTGCTTT
Drd3 - 2 GCAACAGCAAAGTGGAACTCAG GTAGCATCAGTCAGTAAGCAAAGGG
Gabra3 - 1 ATTTGGAGCCTGGGTTAGAAGGCA TACCAAGCCGCTGTGAGATGCTTA
Gabra3 - 2 TAAGCATCTCACAGCGGCTTGGTA TCTAGAGAAGCTCAGAGAGAAGGG
Glra1 - 1 ACCTTGAAACCAAAGGGAGCATGG GGGCAAGGAACTGTTGGG
Grid2 - 1 TTTGAGTCCTGCCTTTCTCAGTCC TAAGAGAAGCGAGTCCGCAAGAGA
Grid2 - 2 TCCTTGCCCTGGTGAAAGAAAGGT CCTACAGCATGCAGATCGTTAGGA
Grid2 - 3 AGGCTATTCAGAAGTCGCGCTGAT TGTGCAGTTGACTGGAAATGCCAC
Calb2 - 1 AGACCTAATATGCTTCAGGCTCAG AGGTGGGATAGAGGGACTGAAAGA
Calb2 - 2 TTCATCCTCCTTTCTGGGAGGCAA TCCTCAGAGCACCTGCTGTCATTT
Calb2 - 3 TGCTCTACATGGTCTTCACAATGA GGTCTGGTAGCCACCTCCAA
Gapdh – P CCGACCTTCACCATCTTGTCT CTGGCCACGCTAATCTGA
Gapdh - E TTGTGACAAAGTGGACATTG AACTTGCCGTGGGTAGAGTC
The positions of the primers are shown in Figure 4.
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We identified a novel group of genes regulated by β-catenin-
LEF1/TCF that encode proteins that underlie the trans-
mission of nerve impulses. These results point to a novel
role for β-catenin in the thalamus, in which β-catenin
is constantly present in the cell nuclei. The identified
and confirmed genes are directly involved in neuronal
excitability, suggesting that β-catenin and LEF1/TCF
transcription factors maintain the proper activity of
thalamocortical circuits. The presented results may
implicate the involvement of β-catenin transcriptional
activity in thalamic pathologies, such as absence epilepsy
and schizophrenia.
Methods
In silico screening and validation of the method
For each human-rat orthologous gene pair in Ensembl
(version 39), 20 kb flanks of the genomic sequence from
−10 kb to +10 kb from TSSs in either species were
aligned using the AVID global alignment algorithm.
Conserved noncoding sequences, defined as sequence
windows at least 100 bp long with at least 75% identitybetween human and rat, were selected as putative regu-
latory regions. The binding sites for LEF1/TCF were sep-
arately predicted using the position weight matrices in
the V$LEFF family (Genomatix Matrix Family Library,
version 6.2) with the MatInspector program for the
human and rat sequences of each CNS pair. V$LEFF
motifs with a nonzero number of instances in both the
human and rat sequences of the same CNS pair (not ne-
cessarily the same number or in the same AVID-aligned
position) were considered conserved. To validate the
method, the group of genes with at least one or at least
two conserved V$LEFF motifs were crossed with known
Wnt target genes listed at http://www.stanford.edu/
group/nusselab/cgi-bin/wnt/target_genes (accessed Janu-
ary 11, 2011). The Wnt targets that had no CNSs, were
indirect targets, or had confusing names were excluded
from this analysis.
GO analysis
The functional annotation tools of DAVID Bioinfor-
matics Resources (http://david.abcc.ncifcrf.gov; accessed
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Figure 5 ChIP analysis of histone acetylation and β-catenin binding to LEF1/TCF motifs of the candidate target genes. (A) The graph
shows the mean percentage of input chromatin precipitated with an anti-H3Ac antibody. Fragments of the Gapdh promoter (Gapdh-P) and exon
(Gapdh-E) were used to determine the signal levels in the case of open and closed chromatin, respectively. The blue area indicates the level of
signal for closed chromatin, assessed based on the precipitation of the exonic fragment of Gapdh. (B) Mean percentage of input chromatin
precipitated with an anti-β-catenin antibody. The blue area indicates the level of background, determined with normal IgG. In some cases
β-catenin binding to chromatin was not detected (ND). n = 4 independent biological samples. Error bars indicate SD. ***p < 0.001, **p < 0.01,
*p < 0.05 (ANOVA).
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http://www.biomedcentral.com/1471-2164/13/635Gene enrichment in annotation terms was measured by
determining the EASE score [91], which is a conservative
correction of Fisher’s Exact p value, for the proportions of
genes that fell into each GO term.
Animal care
To perform this study, we used Wistar rats: 18 adult males
and 12 pregnant females with 19-day-old embryos. Animal
care was in accordance with the European Communities
Council Directive (86/609/EEC). The experimental proce-
dures were approved by the Local Commission for the Eth-
ics of Animal Experimentation no. 1 in Warsaw (approval
no. 883/2008).
Chromatin isolation, shearing, and immunoprecipitation
Three-month-old male Wistar rats were sacrificed by
cervical dislocation, and the brains were removed and
sectioned. Approximately 200 mg of cortical, hippocam-
pal, and thalamic tissues obtained from two rats were
chopped with a razor blade and fixed at room
temperature for 30 min in 1 ml of fresh 3% formalde-
hyde in phosphate-buffered saline (PBS) supplemented
with protease inhibitor cocktail (Roche) in an Eppendorf
tube. Fixation was stopped by adding glycerol to a finalconcentration of 0.125 mM and incubation for a further
10 min to quench formaldehyde. The tissue was then
spun down for 5 min at 1,000 × g and briefly homoge-
nized in ice-cold PBS supplemented with protease in-
hibitor cocktail using an Eppendorf-fitting pestle
homogenizer. After two cycles of washing in PBS (i.e.,
homogenization and centrifugation), the samples were
lysed in 2.5 ml of lysis buffer (1% sodium dodecyl sul-
fate, 10 mM ethylenediamine tetraacetic acid [EDTA],
50 mM TrisHCl, pH 8.1, and protease inhibitor cocktail)
for 30 min at 4°C and then disrupted in a Potter-
Elvehjem homogenizer (~100 strokes). The homogenates
were centrifuged for 10 min at 2,400 × g to pellet the
nuclei, which were then frozen at −80°. After thawing,
the samples were diluted in digestion buffer from the
ChIP-IT Express Enzymatic kit (Active Motif ) and soni-
cated on ice for 10 × 20 s with 40 s breaks at a 50% duty
cycle and 50% power using a Sonopuls Bandeline sonica-
tor to disrupt the nuclei and preshear the chromatin. An
enzymatic shearing protocol using the ChIP-IT Express
Enzymatic kit was then followed. Shearing was con-
ducted with 40 μl of Enzymatic Shearing Cocktail per
one sample for 15 min at 37°C, and the reaction was
stopped with EDTA. Finally, the sheared chromatin was
Figure 6 Expression analysis of the candidate target genes in thalamic neurons (loss-of-function experiment). (A) Subcellular localization
of β-catenin in thalamic neurons in vitro in control (Gfp-expressing; upper panel) and Axin2-expressing (lower panel) cultures. Neuronal marker
NeuN is stained red. β-catenin is green, and nuclei are blue. The arrows point to nuclear β-catenin-positive neurons. Scale bar = 20 μm. The
percentage of β-catenin-positive neurons in every culture is indicated, with p values of the differences (Fisher’s Exact test). (B) Expression of the
candidate LEF1/TCF1 targets Cacna1g, Cacna2d2, Kcna6, Kcnh8, Drd3, Gabra3, Glra1, Grid2, and Calb2, neuronal marker Map2, negative control
Cacna1h, and positive control Lef1 in thalamic cultures transduced with Axin2-expressing adenoviral vector compared with control (Gfp-expressing
cultures). The expression levels are relative to the level of Gapdh. The graph shows the means of all of the results relative to the control, set at 1.
Drd3 mRNA was not detected (ND). n = 9 independent biological samples. Error bars indicate SD. ***p < 0.001, **p < 0.01, *p < 0.05 (Student’s
t-test).
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http://www.biomedcentral.com/1471-2164/13/635separated from debris by centrifugation at 18,000 × g.
This treatment yielded 125–500 bp DNA fragments.
A subsequent immunoprecipitation procedure was per-
formed on an equivalent 30 mg of tissue with 10 μg of
anti-rabbit IgG (Sigma-Aldrich), 5 μg of anti-acetyl-
histone H3 (rabbit polyclonal; Millipore), or 40 μg of
anti-β-catenin (rabbit polyclonal; Santa Cruz Biotechnol-
ogy) antibodies, according to the Millipore protocol
using salmon sperm DNA protein A-agarose (Millipore).
Immunoprecipitated DNA was used as a template for
RT-qPCR with SYBR Green chemistry. The obtained
data were analyzed using the relative quantification
method with the 2-ΔCT formula (DCT = CTinput DNA -
CTimmunoprecipitated DNA; CT is the cycle threshold) and
are presented as a percentage of the input. The primers
used in the ChIP assay are listed in Table 4.
Primary neuronal cultures
Dissociated primary thalamic cells were obtained from
the brains of embryonic day 19 Wistar rat embryos as
described previously [38]. The cells were plated oncoverslips coated with poly-D-lysine (30 μg/ml; Sigma)
at a density of 2.5 × 105 cells per well of a 24-well plate
in Minimal Essential Medium (MEM; Gibco) supple-
mented with 10% fetal bovine serum and 0.2 mM glu-
tamine (Sigma). The next day, the medium was replaced
with Neurobasal (Gibco) supplemented with B27 (Gibco),
0.5 mM glutamine, 12.5 mM glutamate, and penicillin/
streptomycin (Sigma) mixed in a 1:1 ratio with the cor-
tical neuron conditioned medium.Adenoviral constructs and neuron transduction
The construction of recombinant adenoviral plasmids
that expressed Gfp and Axin2 and the preparation and
purification of the adenoviruses were described previ-
ously [38]. On day 4 in vitro, purified virus suspensions
at a multiplicity of infection of 100 were added to each
well of a 24-well plate for 6 h at 37°C. The virus solution
was then removed and replaced with fresh medium.
Seventy-two hours later, the transduced cultures were
collected for RNA isolation or fixation.
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The immunofluorescence analysis of β-catenin
localization was performed as described previously [38].
Briefly, the cells were incubated overnight at 4°C with
anti-β-catenin rabbit antibody (1:250; Santa Cruz Bio-
technology) in a humid chamber followed by incubation
with anti-NeuN mouse antibody (1:150; Chemicon) for
1.5 h at room temperature. All of the antibodies were
diluted in 2% bovine serum albumin. The slides were
acquired under a confocal microscope (Zeiss LSM5 Ex-
citer). The fluorescence intensity of intracellular β-
catenin was analyzed using Cell Profiler Software. Based
on a fluorescent histogram under the control conditions,
two separate cell populations with low and high intensity
were identified, and the intensity threshold between
them was established. In an experimental variant, the
cells with fluorescence greater than the threshold were
counted as β-catenin-positive cells.RNA isolation from brain tissue and neuronal cultures
To isolate RNA from fresh brains, the brains from male,
2-month-old Wistar rats were sectioned, and different
structures were homogenized separately using a Potter-
Elvehjem homogenizer. RNA was extracted with the
RNeasy Lipid Tissue Mini kit with additional DNase
treatment (Qiagen). For neuronal cultures, the cells from
one to three wells of a 24-well plate were pooled to-
gether and homogenized with Qiashredders (Qiagen),
and RNA was isolated with the RNeasy Plus Mini kit
(Qiagen). cDNA was synthesized by reverse transcription
(SuperScript III RnaseH-, Invitrogen).Gene expression analysis by RT-qPCR
All RT-qPCR reactions were performed using the 7900HT
system (Applied Biosystems). Gene profiling in the brain
was performed with custom-designed TaqMan Low Dens-
ity Arrays (Applied Biosystems), hereinafter referred to as
RT-qPCR arrays. Approximately 1.5 μg of cDNA was
loaded per array (384 assays). The obtained data were
analyzed using the relative quantification method with the
2-ΔCT formula (ΔCT = CTtarget - CTGapdh; CT is the cycle
threshold). In thalamic cultures, gene expression levels
were examined in individual qRT-PCR reactions. For Cac-
na1g, Cacna2d2, Kcna6, Knch8, Drd3, Glra1, Gabra3,
Grid2, and Calb1, commercial primers were used (Qia-
gen). For Map2, commercial primers and FAM dye-
labeled TAqMan probes (Applied Biosystems) were used.
Lef1 and Gapdh expression was measured with the fol-
lowing primers: Lef1 (forward, CCCACACGGACAGC-
GACCTA; reverse, TAGGCTCCTFTTCCTTTCTCT), Gapdh
(forward, TGACTCTACCCACGGCAAGTTCAA; reverse,
ACGACATACTCAGCACCAGCATCA). SYBR Green che-
mistry was used, with the exception of Map2, for whichTaqMan was used (Applied Biosystems). The obtained data
were quantified using the relative standard method.
Statistical analysis
Three types of statistical tests were used. Two-tailed
Fisher’s Exact test was used to verify the enrichment
of genes with LEF1/TCF binding sites with the known
Wnt targets (Figure 1). This test was also performed
to calculate p values for the relationships between high
expression in the thalamus and being a putative LEF1/
TCF target (Figure 2; n = 6), and compare the percentage
of β-catenin-positive neurons in two types of thalamic
cultures (Figure 6A).
To calculate p values for differences in gene expression
levels between two brain regions, we ran two-tailed
paired Student’s t-test, using ΔCT values for the results
obtained with the RT-qPCR arrays (Figure 3; n = 6) or
using relative values for the results obtained with indi-
vidual RT-qPCRs (Figure 6; n = 9).
To calculate p values in the ChIP experiment, in which
we compared three brain regions at the same time, we
used repeated measures ANOVA followed by Tukey’s
post hoc test (Figure 5; n = 4).
Additional file
Additional file 1: Excel file with a list of 428 rat genes with at least
two LEF1/TCF motifs in the same CNS.
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